Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...

GuruFocus.com10-10

Net Loss: $1.9 million or $1.16 per share for Q2 2024, compared to $4.2 million or $10.64 per share for Q2 2023. Research and Development Expense: Decreased to $1.9 million for Q2 2024 from $3.1 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474785050?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CCKPjNykSAyQj6dJOYtY9g--~B/aD0xODY7dz0yNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/89ca70d447264cbdd91803c267c6ecac","is_english":true,"pubTime":"2024-10-10 06:27","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474785050","market":"us","top_or_hot":-1,"title":"Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...","media":"GuruFocus.com","content":"<div>\n<p>Net Loss: $1.9 million or $1.16 per share for Q2 2024, compared to $4.2 million or $10.64 per share for Q2 2023.\nResearch and Development Expense: Decreased to $1.9 million for Q2 2024 from $3.1 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bio-path-holdings-inc-bpth-222729169.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 06:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bio-path-holdings-inc-bpth-222729169.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Net Loss: $1.9 million or $1.16 per share for Q2 2024, compared to $4.2 million or $10.64 per share for Q2 2023.\nResearch and Development Expense: Decreased to $1.9 million for Q2 2024 from $3.1 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/bio-path-holdings-inc-bpth-222729169.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BPTH","symbol_name":"Bio-Path Holdings, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/bio-path-holdings-inc-bpth-222729169.html","article_id":"2474785050","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CCKPjNykSAyQj6dJOYtY9g--~B/aD0xODY7dz0yNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/89ca70d447264cbdd91803c267c6ecac"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474785050","pubTimestamp":1728512849,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Net Loss: $1.9 million or $1.16 per share for Q2 2024, compared to $4.2 million or $10.64 per share for Q2 2023.Research and Development Expense: Decreased to $1.9 million for Q2 2024 from $3.1 million in Q2 2023.General and Administrative Expense: $1.2 million for both Q2 2024 and Q2 2023.Cash: $4.0 million as of June 30, 2024, compared to $1.1 million as of December 31, 2023.Net Cash Used in Operating Activities: $4.3 million for the six months ended June 30, 2024, compared to $6.9 million for the same period in 2023.Net Cash Provided by Financing Activities: $7.2 million for the six months ended June 30, 2024.GuruFocus has detected 1 Warning Sign with BPTH.Bio-Path Holdings Inc  strengthened its financial position with a $4 million financing, supporting its clinical development plans.A: Peter Nielsen, CEO, explained that Bio-Path Holdings presented interim results from their Phase 2 study of prexigebersen at the ASCO and EHA meetings. The study involves prexigebersen in combination ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BPTH":"Bio-Path Holdings, Inc."},"translate_title":"Bio-Path Holdings Inc(BPTH)2024年第二季度收益看涨期权亮点：财务改善和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPTH":1},"content_text":"Net Loss: $1.9 million or $1.16 per share for Q2 2024, compared to $4.2 million or $10.64 per share for Q2 2023.\nResearch and Development Expense: Decreased to $1.9 million for Q2 2024 from $3.1 million in Q2 2023.\nGeneral and Administrative Expense: $1.2 million for both Q2 2024 and Q2 2023.\nCash: $4.0 million as of June 30, 2024, compared to $1.1 million as of December 31, 2023.\nNet Cash Used in Operating Activities: $4.3 million for the six months ended June 30, 2024, compared to $6.9 million for the same period in 2023.\nNet Cash Provided by Financing Activities: $7.2 million for the six months ended June 30, 2024.\n\n\nWarning! GuruFocus has detected 1 Warning Sign with BPTH.\n\nRelease Date: August 15, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nBio-Path Holdings Inc (NASDAQ:BPTH) presented compelling interim efficacy data for their lead product candidate, prexigebersen, at prestigious medical meetings, showcasing its potential in treating acute myeloid leukemia (AML).\nThe company announced the development of a molecular biomarker package to enhance the success probability of prexigebersen treatment by identifying patients more likely to respond.\nBP1002, targeting the Bcl-2 protein, completed the second dose cohort in its Phase I/Ib clinical trial, showing promise for patients resistant to current treatments.\nBio-Path Holdings Inc (NASDAQ:BPTH) strengthened its financial position with a $4 million financing, supporting its clinical development plans.\nThe company reported a significant reduction in net loss for the second quarter of 2024 compared to the same period in 2023, indicating improved financial management.\n\n Negative Points \n\nBio-Path Holdings Inc (NASDAQ:BPTH) continues to operate at a net loss, reporting a $1.9 million loss for the second quarter of 2024.\nResearch and development expenses decreased, primarily due to reduced manufacturing expenses, which may indicate potential delays or scaling back in production.\nThe companys cash position, while improved, remains relatively low at $4.0 million as of June 30, 2024, which could limit future operational flexibility.\nDespite promising developments, the company faces challenges in treating refractory relapse AML patients, a population with suboptimal current treatment options.\nThe Phase I/Ib clinical trial of BP1001-A is still in early stages, with data readouts expected later, indicating that it may take time before any potential market entry.\n\n Q & A Highlights \nQ: Can you provide an update on the progress of the prexigebersen clinical trials? A: Peter Nielsen, CEO, explained that Bio-Path Holdings presented interim results from their Phase 2 study of prexigebersen at the ASCO and EHA meetings. The study involves prexigebersen in combination with decitabine and venetoclax for treating AML. The interim data showed promising efficacy signals, particularly in high-risk and refractory relapsed AML patients.\nQ: What are the recent developments regarding BP1002? A: Peter Nielsen, CEO, mentioned that the second dose cohort for the Phase I/Ib clinical trial of BP1002 has been completed. BP1002 targets the Bcl-2 protein and is being tested for relapsed AML, including venetoclax-resistant patients. The trial is progressing with no dose-limiting toxicities reported so far.\nQ: How is Bio-Path Holdings advancing its BP1001-A program? A: Peter Nielsen, CEO, stated that the Phase I/Ib clinical trial of BP1001-A is ongoing, targeting solid tumors such as ovarian, endometrial, pancreatic, and triple-negative breast cancer. The trial aims to evaluate the safety of BP1001-A, which is a modified version of prexigebersen with enhanced nanoparticle properties.\nQ: Could you elaborate on the financial performance for the second quarter of 2024? A: Anthony Price, SVP of Finance, reported a net loss of $1.9 million for the quarter, a decrease from the $4.2 million loss in the same period last year. The reduction in loss was attributed to decreased manufacturing expenses and increased patient enrollment in clinical trials.\nQ: What is the status of the BP1003 program targeting the STAT3 protein? A: Peter Nielsen, CEO, highlighted that BP1003 is being developed to target the STAT3 protein, which is involved in various cancers. The company has identified a method for oligo detection in plasma, which will enable final safety testing and the submission of an IND application to the FDA.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474785050"}